MICHAEL SHECHTER: Influence Statistics

MICHAEL SHECHTER

MICHAEL SHECHTER

Leviev Cardiothoracic and Vascular Center, Chaim Sheba Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Israel.

MICHAEL SHECHTER: Expert Impact

Concepts for which MICHAEL SHECHTER has direct influence: Odyssey outcomes , Alirocumab treatment , Placebo patients , Patients alirocumab , Incident type , Patients prediabetes , 2 diabetes .

MICHAEL SHECHTER: KOL impact

Concepts related to the work of other authors for which for which MICHAEL SHECHTER has influence: Blood pressure , Cardiovascular disease , Arterial hypertension , Hypertensive patients , Heart failure , Diabetes mellitus , Renal denervation .

KOL Resume for MICHAEL SHECHTER

Year
2021

Leviev Cardiothoracic and Vascular Center, Chaim Sheba Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Israel.

Prominent publications by MICHAEL SHECHTER

KOL-Index: 18000 . BACKGROUND: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4-1·8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein ...
Known for Odyssey Outcomes | Coronary Syndrome | Patients Alirocumab | Controlled Trial
KOL-Index: 3840 . BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. OBJECTIVES: In a ...
Known for Cardiovascular Outcomes | Acute Coronary | Statin Treatment | Mace Ldlc
KOL-Index: 3754 . OBJECTIVE: In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incident type 2 diabetes and effects of treatment with alirocumab, a PCSK9 inhibitor. RESEARCH ...
Known for 2 Diabetes | Levels Lipoproteina | Acute Coronary Syndrome | Proprotein Convertase
KOL-Index: 797
Known for Arterial Hypertension | 2018 Esc | Esh Guidelines

Key People For Odyssey Outcomes

Top KOLs in the world
#1
Robert Pordy
acute coronary syndrome odyssey outcomes cardiovascular events
#2
CORINNE G Hanotin
monoclonal antibodies acute coronary syndrome cardiovascular outcomes
#3
Andreas Michael Zeiher
endothelial cells myocardial infarction heart failure
#4
Robert A Harrington
acute coronary syndromes myocardial infarction glycoprotein iib
#5
Gregory G Schwartz
acute coronary syndrome cardiovascular events odyssey outcomes
#6
Robert Patrick Giugliano
atrial fibrillation myocardial infarction acute coronary

Leviev Cardiothoracic and Vascular Center, Chaim Sheba Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Israel.